Pomerantz Law Firm Investigates Claims Against Larimar Therapeutics Investors
Pomerantz LLP has initiated an investigation into claims made by investors of Larimar Therapeutics, Inc., concerning potential securities fraud or other unlawful business practices.
New York, NY – July 9, 2026 – Pomerantz LLP, a distinguished law firm, announced today that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (NASDAQ: LRMR). The investigation is examining whether Larimar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Concerns were first raised in September 2025 when Larimar released data from an ongoing study of its drug nomlabofusp for the treatment of Friedreich's Ataxia. While the company characterized the data as "positive," its press release disclosed instances of anaphylaxis (severe allergic reactions) in seven participants. Following this announcement, Larimar's stock price dropped by 33.66%.
The situation intensified in June 2026 when Larimar updated its study data and announced the submission of its Biologics License Application (BLA) to the FDA. The company again described the data as "positive," but also revealed an ongoing safety signal, with anaphylaxis reported in 10 out of 43 patients. This news resulted in another significant drop in Larimar's stock price, falling 12.57%.
Pomerantz LLP is now examining these events and potential violations of securities laws. Investors who have experienced losses and wish to learn more about their options or participation in a potential class action are encouraged to contact the firm.